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Urothelial cell carcinoma of the urinary bladder with metastasis to the skull is extremely rare. We
present a case of occipital bone metastasis arising from a previously veriﬁed bladder urothelial carci-
noma. An 81-year-old woman presented with a painless, nonpulsatile mass in the left occipital region of
the scalp that had progressively increased for 1 year. Skull radiography demonstrated a large osteolytic
lesion in the left occipital bone. Computed tomography of the head showed a 6.5 cm  6.0 cm skull defect
from the midline to the left occipital bone, overlying the posterior superior sagittal sinus. The patient
underwent a wide craniectomy with en bloc removal of the mass. Because of widespread disease, the
patient died 3 months after surgery.
Copyright  2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Tumor metastasis to the skull occurs in various malignancies,
most often from the lung, breast, prostate, and thyroid. Urothelial
carcinoma of the urinary bladder (UCB) usually disseminates to the
liver, lung, and bone marrow. Skull metastasis from UCB is un-
common, and occurs in less than 1.0% of patients harboring this
pathology.
UCB is the fourth most common cancer in white men, with a
male to female ratio of 8:1 in those older than 50 years [1]. Women
and black people are most likely to present with advanced disease
[2,3]. When distant metastasis is present, the disease becomes
invasive with a poor outcome. A solid mass causing lytic lesions in
the skull is suggestive of metastasis and can present with various
radiological ﬁndings. Skull metastasis can cause many clinical
manifestations including cosmetic problems, pain, local swelling,
skin ulcerations, bleeding, neurological deﬁcit, dural sinus
compression, and sinus thrombosis.rgery, Chung Shan Medical
th Road, Taichung, Taiwan.
elief Tzu Chi Foundation. PublisheBone metastasis noticeably worsens the prognosis of cancer
patients because of organ inﬁltration or progression of the
original cancer. If cranial metastases overlie or invade the dural
venous sinus, surgical resection may provide effective palliation
of symptomatic skull metastasis. Focal palliative radiotherapy
might also be helpful in relieving symptoms or preventing
recurrence [4,5].
2. Case report
An 81-year-old woman presented to the Department of
Neurosurgery, Chung Shan Medical University Hospital, Taichung,
Taiwan, with painless, progressively increasing swelling in the left
occipital region close to the midline of the scalp (Fig. 1A). High
grade, lamina propria inﬁltrative UCB following transurethral
resection (pT1N0M0, grade 1) had been diagnosed in this patient 1
year previously. After admission, skull radiography and contrast-
enhanced computed tomography (CT) demonstrated a
6 cm  6 cm  6.5 cm lytic lesion in the left occipital bone
destroying the outer and inner tables, and extending extradurally
under the scalp (Fig. 1B and C). A total tumor resection via a left
occipital craniectomy was performed. Grossly, the tumor was
elastic and immobile with a thickened capsule and central necrosis,
expanding intracranially and overlying the posterior superior
sagittal sinus (Fig. 2). The entire tumor along with the involved
bone was removed, and the portion overlying the sinus was gentlyd by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. (A) Lateral view of the head demonstrates a scalp mass. (B) Plain radiography of the skull depicts an osteolytic defect in the occipital bone. (C) Computed tomography reveals
a defect in the left occipital bone and a soft mass compressed the superior sagittal sinus.
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resection of the tumor was accomplished with minimal blood loss.
An acrylic plate was used for the bony defect. Histopathologic ex-
amination showed a papillary arrangement of cancer cells with
central necrosis (Fig. 3A and B). The individual cancer cells showed
pleomorphic nuclei and prominent nucleoli with frequent mitoses.
The skull was inﬁltrated by cancer cells without involvement of the
overlying dermis (Fig. 3C). Immunohistochemical stains with p63,
CK20, and CK7 were all positive, thus conﬁrming the diagnosis of
metastatic urothelial cell carcinoma (Fig. 3DeF).
Three weeks after surgery, technetium-99m methylene
diphosphonate (99mTc-MDP) bone scintigraphy showed abnormal
ring-shaped uptake in the occipital skull related to postcraniectomy
changes, but no other abnormal bone or vertebral uptake (Fig. 4).
The occipital skull was the site of the initial distal metastasis
originating from UCB. The patient had an uneventful recovery, and
completed whole brain radiotherapy with 5040 Gy in 28 fractions.
Because of refractory gastrointestinal bleeding and uremia, the
patient died 3 months after the initial diagnosis of skull metastasis.Fig. 2. Intraoperative photographs. (A) An elastic, immobile, occipital mass on the left3. Discussion
The incidence of skull metastasis from malignant tumors is
increasing, most commonly from breast cancer, pulmonary cancer,
and prostate cancer. Breast cancer accounts for 55% of metastatic
skull lesions, the highest rate of these cancers [6]. This report shows
a rare case of skull metastatic urothelial cell carcinoma producing
destruction of the left occipital bone. It also emphasizes an atypical
appearance of urothelial cell carcinoma.
Skull metastasis from UCB is uncommon. Babaian et al [7] re-
ported 107 cases of metastatic urothelial cell carcinoma; the most
common site for metastases was the lymph nodes (78%), followed
by the liver (38%), lung (36%), bone (27%), and adrenal glands (21%),
with rare involvement (1e8%) of the heart, brain, kidney, spleen,
pancreas, meninges, uterus, ovaries, prostate, and testes. Skull
metastasis was found in only one case (1/107), accounting for less
than 1% [7].
Skull metastases are classically osteolytic and hypervascular
with an expansile palpable scalp mass, as in our case. In 2003, Starkside of the skull is seen. (B) The tumor capsule is thickened with central necrosis.
Fig. 3. Histopathology of a biopsy specimen from the skull lesion. (A) Low-power view shows the skull bone tumor has papillary fronds with frequent branching and fusion
[hematoxylin and eosin (H&E) stain, 40]. (B) High-power view shows atypical tumor cells that are pleomorphic with hyperchromatic nuclei, prominent nucleoli, and frequent
mitoses (H&E, 200). (C) The skull is inﬁltrated by tumor cells (H&E, 100). (D) Immunostaining with CK20. (E) Immunostaining with p63. (F) Immunostaining with CK7.
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tases from breast carcinoma, malignant melanoma, colorectal
cancer, prostate cancer, parotid cancer, leiomyosarcoma, soft-tissue
sarcoma, and Ewing sarcoma. The most common symptoms were
painless swelling in ﬁve patients (42%), local pain and neurological
deﬁcit (facial palsy, hypoesthesia of the trigeminal nerve area) in
three patients (25%), and dural invasion with compression of the
dural sinuses causing increased intracranial pressure,
meningeal irritation, and focal neurological signs in six patients
(50%).
The mechanism of skull bone metastasis from urothelial cell
carcinoma has not been completely elucidated. In general, there are
ﬁve mechanisms by which a metastatic tumor spreads from a pri-
mary site to the skull bone: direct extension from an intracranial
primary tumor, hematogenous spread, lymphatic spread, direct
meningeal extension, and leptomeningeal seeding. The most
commonmechanism of urothelial cell carcinomametastasis is local
lymphatic spread. Brain or skull metastasis most likely occurs by
hematogenous spread rather than other mechanisms, and is
regarded as a late appearance of systemic extension. Some identi-
ﬁed risk factors, such as radiation exposure or tobacco use, increase
the incidence of brain or skull metastasis in urothelial cellcarcinoma. In 2010, Ogunyemi et al [8] reported on 734 patients
with genitourinary tumors, of whom 75% with brain metastases
had a strong history of tobacco use.
Plain skull radiography is the most frequent initial step in pa-
tients with clinical suspicion of a bone lesion. CT and magnetic
resonance imaging (MRI) enable screening for important infor-
mation prior to surgery, CT can determine the degree of bony
destruction, and MRI contributes to understanding of the tumor
type, location, multiplicity, and relationship to the brain, dural si-
nus, and nerve tissue. 99mTc-MDP bone scintigraphy and 18F-ﬂuo-
ride positron emission tomography/CT (PET/CT) are usually used to
detect bony metastases [9,10]. 18F-ﬂudeoxyglucose (18F-FDG) PET
has been reported to be more sensitive, speciﬁc, and accurate than
99mTc-MDP bone scintigraphy in patients with skeletal metastases
in urinary bladder carcinoma [11].
Most metastatic skull tumors may not directly inﬂuence the
survival time of patients, but are clinically signiﬁcant in relation to
quality of life. The prognosis of skull metastatic tumors varies based
on the type of primary cancer. In one study, the median interval
between treatment of the primary cancer and detection of skull
metastases was 4 years (mean, 6 years; range, 0e16 years, 5
months) [6]. The mean survival time from skull metastasis was 19.5
Fig. 4. (A) 99mTc-MDP bone scintigraphy shows several consecutive hot spots in the
right rib cage, most likely rib fractures. (B) 99mTc-MDP bone scintigraphy shows
increased ring-shaped uptake in the occipital skull, consistent with postcraniectomy
changes.
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tasis of urothelial cell carcinoma has seldom been studied.
Mahmoud-Ahmed et al [12] reported the overall survival after brain
metastasis in 16 patients with UCB was poor, with a median sur-
vival time of 2 months (range, 0.5e12.75 months). Babaian et al [7]
reported a median survival time of 3 months (range, 1e58 months)
in 107 patients with urothelial cell carcinoma with various sites of
metastasis. The causes of death were sepsis (42%), carcinomatosis
(28%), and uremia (15%) [7]. Our patient died because of gastroin-
testinal bleeding and uremia.
There are four modalities in the treatment of skull metas-
tasis: surgical removal, irradiation, chemotherapy, and endocri-
nological therapy. Conventional fractionated radiation therapy
remains the primary treatment for skull metastasis. However,
some patients are candidates for surgical resection when skull
metastases compress/inﬁltrate the dural venous sinus. Michael
et al [5] reported 13 patients with skull metastasis involving the
dural sinus, most of whom beneﬁted from surgery and/or
radiotherapy in terms of pain control or improvement of
neurologic deﬁcits. The beneﬁts from surgical removal of skullmetastasis include a rapid decompression of perifocal edema,
elimination of mass effects, a decrease in dural sinus compres-
sion, and improved cognitive function.
Histologically, the metastatic tumor is often poorly differen-
tiated, and immunohistochemical staining is needed to ﬁnd its
primary origin. CK20 and p63 are regularly used to differentiate
between urothelial cell carcinoma and squamous cell carcinoma.
Urothelial cell carcinoma frequently expresses both CK20 and
p63 positivity. Gruver et al [13] showed a positive immuno-
phenotype with strongly expressed CK7 (100%), CK20 (53%), and
p63 (78%) in 37 cases of primary invasive tumors of the urinary
bladder. Ogata et al [14] reported that CK20 was strongly asso-
ciated with recurrence and histologic grades in cases of uro-
thelial neoplasms.
Generally, multitherapeutic approaches to bladder cancer
surgery, chemotherapy, and radiotherapy improve the patient’s
long-term survival. Although there is no direct relationship be-
tween the prognosis and skull metastasis, the prognosis is
usually poor in patients with urothelial cell carcinoma with skull
metastasis. Metastasis of urothelial cell carcinoma to the skull is
attributed to the uncontrolled progression or inﬁltration of the
original cancer. Early detection of bone metastasis is therefore
important for selecting appropriate treatment as well as a better
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